Tatjana S Potpara1,2, Gregory Y H Lip3,4, Nikolaos Dagres5, Harry J M G Crijns6,7, Giuseppe Boriani8, Paulus Kirchhof9,10,11, Elena Arbelo12,13,14, Irina Savelieva15, Radoslaw Lenarczyk16, Laurent Fauchier17, Aldo P Maggioni18,19, Chris P Gale20. 1. School of Medicine, Belgrade University, Dr Subotica 8, 11000 Belgrade, Serbia. 2. Cardiology Clinic, Clinical Centre of Serbia, Visegradska 26, 11000 Belgrade, Serbia. 3. Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. 4. Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark. 5. Department of Electrophysiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. 6. Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands. 7. Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands. 8. University of Modena and Reggio Emilia, Modena, Italy. 9. Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, Medical School, University of Birmingham, Edgbaston, Birmingham, UK. 10. University Heart and Vascular Center, UKE Hamburg, Hamburg, Germany. 11. German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Barcelona, Spain. 12. Department of Cardiology, Cardiovascular Institute, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain. 13. Instit d'Investigació August Pi i Sunyer (IDIBAPS), Barcelona, Spain. 14. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. 15. Division of Cardiac and Vascular Sciences, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK. 16. Department of Cardiology, Congenital Heart Disease and Electrotherapy, Silesian Medical University, Silesian Centre for Heart Diseases, Silesian Medical University, 9 Curie-Sklodowskiej St., Zabrze, Poland. 17. Service de Cardiologie, Centre Hospitalier Universitaire Trousseauet Faculté de Médecine EA7505, Université de Tours, Tours, France. 18. EURObservational Research Programme, European Society of Cardiology, 2035 Route des Colles,Biot, 06903 Sophia-Antipolis, France. 19. Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy. 20. Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Abstract
AIMS: The European Society of Cardiology (ESC) EURObservational Research Programme (EORP)-Atrial Fibrillation (AF) III Registry aims to identify contemporary patterns in AF management in clinical practice, assess their compliance with the 2016 ESC AF Guidelines, identify major gaps in guideline implementation, characterize the clinical practice settings associated with good vs. poor guideline implementation and assess and compare the 1-year outcome of guideline-adherent vs. guideline non-adherent management strategies. METHODS AND RESULTS: Consecutive adult AF patients (n = 8306) were enrolled between 1 July 2018 and 15 July 2019, and individual patient data were prospectively collected across 192 centres and 31 participating countries during the 3-month enrolment period per centre. The Registry collected baseline and 1-year follow-up data in the eight main domains: patient demographic/enrolment setting, AF diagnosis/characterization, diagnostic assessment, stroke prevention treatments, arrhythmia-directed therapies, integrated AF management, major outcomes (death, non-fatal stroke or systemic embolic event, and non-fatal bleeding event), and the quality of life questionnaire. CONCLUSION: The EORP-AF III Registry is an international, prospective registry of care and outcomes of patients treated for AF, which will provide insights into the contemporary patterns in AF management, ESC AF Guidelines implementation in routine practice and barriers to optimal management of this highly prevalent arrhythmia. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: The European Society of Cardiology (ESC) EURObservational Research Programme (EORP)-Atrial Fibrillation (AF) III Registry aims to identify contemporary patterns in AF management in clinical practice, assess their compliance with the 2016 ESC AF Guidelines, identify major gaps in guideline implementation, characterize the clinical practice settings associated with good vs. poor guideline implementation and assess and compare the 1-year outcome of guideline-adherent vs. guideline non-adherent management strategies. METHODS AND RESULTS: Consecutive adult AF patients (n = 8306) were enrolled between 1 July 2018 and 15 July 2019, and individual patient data were prospectively collected across 192 centres and 31 participating countries during the 3-month enrolment period per centre. The Registry collected baseline and 1-year follow-up data in the eight main domains: patient demographic/enrolment setting, AF diagnosis/characterization, diagnostic assessment, stroke prevention treatments, arrhythmia-directed therapies, integrated AF management, major outcomes (death, non-fatal stroke or systemic embolic event, and non-fatal bleeding event), and the quality of life questionnaire. CONCLUSION: The EORP-AF III Registry is an international, prospective registry of care and outcomes of patients treated for AF, which will provide insights into the contemporary patterns in AF management, ESC AF Guidelines implementation in routine practice and barriers to optimal management of this highly prevalent arrhythmia. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Andreas Metzner; Anna Suling; Axel Brandes; Günter Breithardt; A John Camm; Harry J G M Crijns; Lars Eckardt; Arif Elvan; Andreas Goette; Laurent M Haegeli; Hein Heidbuchel; Josef Kautzner; Karl-Heinz Kuck; Luis Mont; G Andre Ng; Lukasz Szumowski; Sakis Themistoclakis; Isabelle C van Gelder; Panos Vardas; Karl Wegscheider; Stephan Willems; Paulus Kirchhof Journal: Europace Date: 2022-04-05 Impact factor: 5.214